Subgroup Analyses Need Confirmation In Independent Trials - Duke’s George
Executive Summary
Findings from subgroup analyses need to be confirmed in an independent trial to be viewed as conclusive, Duke University biostatistician Stephen George said at a recent FDA seminar
You may also be interested in...
Tarceva Pancreatic Cancer Data Do Not Support Broad Use – ASCO Review
Results from Genentech/OSI's Phase III trial of Tarceva (erlotinib) in advanced pancreatic cancer do not support broad use, according to a review at the American Society of Clinical Oncology annual meeting
Tarceva Pancreatic Cancer Data Do Not Support Broad Use – ASCO Review
Results from Genentech/OSI's Phase III trial of Tarceva (erlotinib) in advanced pancreatic cancer do not support broad use, according to a review at the American Society of Clinical Oncology annual meeting
Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July
FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated